1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Allergan’s abicipar pegol is a novel, long-acting anti-VEGF drug that is based on the DARPin technology. It is undergoing clinical development as a potential treatment for patients with wAMD, and a Phase III clinical trial is expected to begin in Q2 2015.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Abicipar Pegol including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Abicipar Pegol for the top country from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Abicipar Pegol performance.
- Obtain sales forecast for Abicipar Pegol from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table Of Contents

Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 21
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
6 Unmet Need and Opportunity 52
6.1 Overview 52
6.2 Treatment for Dry AMD 53
6.2.1 Unmet Need 53
6.2.2 Gap Analysis 55
6.2.3 Opportunity 57
6.3 Longer-Acting Anti-VEGF Drug Therapy 59
6.3.1 Unmet Need 59
6.3.2 Gap Analysis 61
6.3.3 Opportunity 61
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 62
6.4.1 Unmet Need 62
6.4.2 Gap Analysis 63
6.4.3 Opportunity 64
6.5 Less Invasive Drug Formulations 64
6.5.1 Unmet Need 64
6.5.2 Gap Analysis 65
6.5.3 Opportunity 66
6.6 Awareness and Earlier Patient Diagnosis 67
6.6.1 Unmet Need 67
6.6.2 Gap Analysis 68
6.6.3 Opportunity 68
6.7 Home Monitoring of AMD Progression 69
6.7.1 Unmet Need 69
6.7.2 Gap Analysis 70
6.7.3 Opportunity 71
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 74
8 Abicipar pegol 77
8.1 Overview 77
8.2 Efficacy 79
8.3 Safety 80
8.4 Dosing and Formulation 81
8.5 Potential Clinical and Commercial Positioning 81
8.6 SWOT Analysis 82
8.7 Forecast 82
9 Appendix 84
9.1 Bibliography 84
9.2 Abbreviations 98
9.3 Methodology 101
9.4 Forecasting Methodology 101
9.4.1 Diagnosed ME and AMD Patients 102
9.4.2 Percentage of Drug-Treated Patients 102
9.4.3 General Pricing Assumptions 102
9.4.4 Pricing of Pipeline Agents 103
9.5 Primary Research - KOLs Interviewed for this Report 104
9.6 Primary Research - High-Prescribers Survey 105
9.7 About the Authors 106
9.7.1 Analyst 106
9.7.2 Therapy Area Director 106
9.7.3 Global Head of Healthcare 107
9.8 About GlobalData 108
9.9 Disclaimer 108

1.1 List of Tables

Table 1: ARM System Classification of AMD 21
Table 2: Symptoms of AMD 22
Table 3: National and International Treatment Guidelines for ME and AMD 35
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36
Table 5: Leading Treatments for ME and AMD, 2014 51
Table 6: Unmet Needs and Opportunities in ME and AMD 53
Table 7: Promising Drugs in Clinical Development for ME and AMD 74
Table 8: Comparison of Drugs in Development for ME and AMD, 2014 75
Table 9: Product Profile - Abicipar pegol 79
Table 10: SWOT Analysis - Abicipar pegol, 2014 82
Table 11: Global Sales Forecast ($m) for Abicipar Pegol, 2013-2023 83
Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 105

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 14
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 23
Figure 3: Color Fundus Photographs of Dry and Wet AMD 23
Figure 4: FAF Imaging of GA 24
Figure 5: Imaging of wAMD 25
Figure 6: CMT in DME 31
Figure 7: RVOs (BRVO and CRVO) on an FA 31
Figure 8: Increased CRT in ME-RVO 32
Figure 9: ME Clinical Treatment Flowchart 42
Figure 10: AMD Clinical Treatment Flowchart 49
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 76
Figure 12: Abicipar Pegol's Clinical Development in wAMD and DME 79
Figure 13: Clinical and Commercial Positioning of abicipar pegol 81

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Europe Market Report for Corneal Topographers 2017 - MedCore

Europe Market Report for Corneal Topographers 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

  • $ 4995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description More integration was seen in the overall market for diagnostic and interventional ophthalmic devices. In the diagnostic space, practitioners are enjoying better, more flexible diagnostic capabilities ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry in New Zealand

  • February 2017
    11 pages
  • Diabetes  

  • New Zealand  

    United States  

View report >

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Healthcare Statistics in the UK

  • February 2017
    48 pages
  • Mortality  

    Healthcare  

    Smoking Statist...  

  • United Kingdom  

View report >

Related Market Segments :

Eye Disease
Therapy
Ophthalmology

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.